Table 1. Patient characteristics.
| All patients | EGFR Group | BRCA1 Groups | ||||
| Low | Intermediate | High | ||||
| N = 123 | N = 12 | N = 38 | N = 40 | N = 33 | ||
| N (%) | N (%) | N (%) | N (%) | N (%) | ||
| Age | Median(range) | 60 (36–78) | 60 (42–70) | 60 (36–77) | 58 (43–78) | 60 (42–75) |
| Gender | Female | 38 (30.9) | 9 (75) | 15 (39.5) | 11 (27.5) | 3 (9.1) |
| Male | 85 (69.1) | 3 (25) | 23 (60.5) | 29 (72.5) | 30 (90.9) | |
| Smoker | Current | 40 (32.5) | 1 (8.3) | 7 (18.4) | 18 (45) | 14 (42.4) |
| Never | 26 (21.1) | 7 (58.3) | 8 (21.1) | 8 (20) | 3 (9.1) | |
| Former | 57 (46.4) | 4 (33.4) | 23 (60.5) | 14 (35) | 16 (48.5) | |
| Race | Caucasian | 122 (99.2) | 12 (100) | 38 (100) | 39 (97.5) | 33 (100) |
| Other | 1 (0.8) | 0 (0) | 0 (0) | 1 (2.5) | 0 (0) | |
| ECOG PS | 0 | 44 (35.8) | 6 (50) | 15 (41.7) | 12 (30.7) | 11 (33.3) |
| 1 | 68 (55.3) | 5 (41.7) | 20 (55.5) | 23 (58.9) | 20 (60.6) | |
| 2 | 8 (6.5) | 1 (8.3) | 1 (2.8) | 4 (10.4) | 2 (6.1) | |
| NR | 3 (2.4) | 0 | 2 | 1 | 0 | |
| Histology | Adeno | 83 (67.5) | 8 (66.7) | 27 (71.1) | 27 (67.5) | 21 (63.) |
| BAC | 10 (8.1) | 3 (25) | 5 (13.2) | 2 (5) | 0 (0) | |
| LCC | 14 (11.4) | 1 (8.3) | 2 (5.3) | 5 (12.5) | 6 (18.2) | |
| NOS | 16 (13) | 0 | 4 (10.5) | 6 (15) | 6 (18.2) | |
| Stage | III | 21 (17.1) | 3 (25) | 10 (26.3) | 5 (12.5) | 3 (9.1) |
| IV | 102 (82.9) | 9 (75) | 28 (73.7) | 35 (87.5) | 30 (90.9) | |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; NR, not recorded; adeno, adenocarcinoma; BAC, bronchioloalveolar carcinoma; LCC, large cell carcinoma; NOS, non-specified;